Companion Animal Pharmaceuticals Market

Companion Animal Pharmaceuticals Market by Indication (Infectious Diseases, Antibiotics, Parasiticides, Vaccines, Pain), Animal Type (Dogs, Cats, Horses), Distribution Channel (Veterinary Hospitals & Clinics), COVID-19 Impact - Global Forecast to 2026

Report Code: MD 7870 Apr, 2021, by marketsandmarkets.com

[238 Pages Report] The global companion animal pharmaceuticals market is projected to reach USD 18.5 billion by 2026 from USD 12.8 billion in 2021, at a CAGR of 7.6% during the forecast period. The growth in this market is majorly driven by the growth in companion animal ownership, rising prevalence of zoonotic diseases, rising demand for pet insurance with the growing animal health expenditure, and initiatives by various government agencies and animal associations. On the other hand, the limited number of new antibiotics, rising pet care costs, and rising cost of vaccine storage are expected to restrain the growth of this market during the forecast period.

Companion Animal Pharmaceuticals Market

To know about the assumptions considered for the study, download the pdf brochure

Covid-19 Impact on the Companion Animal Pharmaceuticals Market

Since the beginning of 2020, an increasing number of countries across the globe have shut down their borders and limited transportation and travel to contain the coronavirus (COVID-19) outbreak, creating impediments for international trade and transportation. This disrupted the supply chain for the companion animal pharmaceuticals market, temporarily leading to a decline in the demand for these products. According to the American Veterinary Medical Association (AVMA), there is no evidence that animals are playing a significant epidemiological role in the spread of human COVID-19 infections; however, because animals and people can sometimes share diseases, it is still recommended that people with suspected/confirmed infections limit contact with animals and take precautions while handling pets or animals.

Companion Animal Pharmaceuticals Market Dynamics

Driver: Growing prevalence of zoonotic diseases

Some pathogens, known as zoonotic, can be transmitted from animals to humans. Examples of zoonotic diseases include rabies, salmonellosis, plague, brucellosis, and Lyme disease. Animals also share our susceptibility to certain diseases and environmental hazards and can serve as an early warning for potential human infections. Over the past two decades, the incidence of zoonotic diseases has increased globally, primarily as a result of the increased pet population. According to the International Livestock Research Institute (ILRI), 13 zoonoses cause 2.4 billion cases of human diseases and 2.2 million deaths every year. Toxoplasmosis—which is transmitted via cat feces—is quite common, with 10–20% of the UK population and 22% of the US population expected to carry the parasite as cysts. Cats with chronic bacteremia are mainly infected through the saliva, and there is a high risk of transmittance from young adult cats. Although cats are asymptomatic carriers, weaker individuals can develop generalized infections. Many of the emerging and re-emerging infectious disease threats are vector-borne diseases transferred to animals and humans from arthropods.

Restraint: Rising pet care costs

According to the APPA National Pet Owners Survey (2019), the average household in the US spent USD 731 on routine doctor and surgical visits for dogs in 2019, an increase of 47% as compared to a decade ago. Similarly, USD 427 was spent on routine doctor and surgical visits for cats in 2019. In Germany, the annual veterinary cost is ~USD 162.9 (EUR 140) per dog and USD 75.61 (EUR 65) per cat. In Japan, pet owners spend around USD 2,000–3,000 (JPY 200,000–300,000) annually on pet health. Although the pet insurance market is expanding, the number of animals covered for treatments is still very less. As a result, animal owners generally bear the majority of the cost of treatments. Also, according to the Society for Practicing Veterinary Surgeons, along with the increasing pet insurance, the cost of veterinary treatment is rising by about 12% a year.

Opportunity: Lucrative growth opportunities in emerging markets

Historically, the adoption of animal healthcare products in veterinary practices and pet owners in India and China have been comparatively lower than that in developed markets such as the US and some European countries. With the surge in companion animal population and increasing animal health expenditure, India and China showcase high-growth opportunities for players in the APAC animal health industry. Also, many players from international markets are focusing on investing in these countries to expand their presence and ensure long-term revenue growth.

Challenge: Stringent regulatory approval process for drugs

The US FDA; Canadian Food Agency; European Medical Agency; Ministry of Agriculture, Forestry, and Fisheries (MAFF); and Australian Pesticides and Veterinary Medicines Authority (APVMA) are some of the major regulatory bodies that approve medicines used for veterinary purposes. The Veterinary International Committee for Harmonization (VICH) also plays a significant role in bringing together regulatory authorities in the US, Europe, and Japan; it also harmonizes guidelines and technical requirements to register veterinary products. These regulatory bodies have set stringent regulations to approve veterinary pharmaceutical products. Regulatory standards for the approval of new veterinary pharmaceutical products, including antimicrobials, antibiotics, vaccines, parasiticides, and other pharmaceutical products, are also very stringent in countries such as Australia, Japan, and China.

The dermatologic diseasessegment is expected to grow at the highest CAGR, in the companion animal pharmaceuticals market by indication, in the forecast period

Based on the prescription of pharmaceuticals for a number of disorders prevailing in animals, the companion animal pharmaceuticals market is segmented into infectious diseases, dermatologic diseases, orthopedic diseases, pain, behavioral disorders, and other indications. The dermatologic diseases segment is expected to grow at the highest CAGR during the forecast period. The increasing prevalence of arthritis, rising need for advanced orthopedic drugs, and growing pet population are some of the key factors driving the growth of this segment.

The dogs segment holds the largest share in the animal type segment, in the forecast period.

Based on animal type, the companion animal pharmaceuticals market is segmented into dogs, cats, horses, and other companion animals. The dogs segment accounted for the largest market share in 2020. The large share of this segment is attributed to the increasing dog population and rising ownership rate, increasing prevalence of zoonotic diseases and other skin allergies in dogs, rising canine healthcare expenditure, and the increasing number of pet insurers across the globe.

Veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market by distribution channel segment in the forecast period.

Based on the distribution channel, the global companion animal pharmaceuticals market is segmented into veterinary hospitals, veterinary clinics, and retail pharmacies. The veterinary hospitals segment is expected to grow at the highest CAGR during the forecast period. The higher adoption of animal parasiticides and antibiotics in hospital settings, increasing incidence of infectious diseases, growing number of veterinary hospitals, growing ownership of companion animals, increasing veterinary expenditure, and growing awareness about animal health in developing countries, are some of the key factors driving the growth of this segment.

North America held the largest share of the companion animal pharmaceuticals market, by region.

In 2020, North America accounted for the largest share of the companion animal pharmaceuticals market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the well-established base of animal health industries, the high adoption of companion animals, rising incidence of parasitic infections, the large number of hospitals and clinics, growing pool of veterinarians, and growing expenditure on animal health in the region. The growing number of research activities and funding and awareness campaigns in the field of veterinary health management is also expected to drive the growth of this market.

Companion Animal Pharmaceuticals Market  by Region

Key Market Players

The prominent players in the global companion animal pharmaceuticals market are Zoetis Inc. (US) Merck & Co., Inc. (US) Boehringer Ingelheim GmbH (Germany) Elanco Animal Health Incorporated (US), Virbac (France), Ceva Santι Animale (France), Vetoquinol S.A. (France), and Dechra Pharmaceuticals plc (UK).

Scope of the report

Report Metric

Details

Market Size available for years

2019-2026

Base Year Considered

2020

Forecast period

2021-2026

Forecast Unit

Value(USD Billion)

Segments covered

Indication, Animal Type, Distribution Channels

Geographies covered

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe(RoE)
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
  • Middle East & Africa

Companies Covered

Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Elanco Animal Health Incorporated (US), Ceva Santι Animale (France), Virbac (France), Vetoquinol S.A. (France), Dechra Pharmaceuticals plc (UK), Chanelle Pharma (Ireland), Kyoritsu Seiyaku (Japan), Zydus Animal Health and Investments Limited (India), Tianjin Ringpu Bio-Technology Co., Ltd. (China), HIPRA (Spain), Norbrook Holdings Limited (UK), Inovet (Belgium), Endovac Animal Health (US), ECO Animal Health Group plc (UK), Indian Immunologicals Ltd. (India), ALS Pvt. Ltd. (India), and Lutim Pharma Pvt. Ltd. (India).

The research report categorizes the market into the following segments and subsegments:

Companion Animal Pharmaceuticals Market, By Indication

  • Infectious Diseases
    • Antibiotics & Antimicrobials
    • Parasiticides
    • Vaccines
    • Other Companion Animal Pharmaceuticals
  • Dermatologic Diseases
  • Pain
  • Orthopedic Diseases
  • Behavioral Diseases
  • Other Indications

Companion Animal Pharmaceuticals Market, By Animal Type

  • Dogs
  • Cats
  • Horses
  • Other Companion Animals

Companion Animal Pharmaceuticals Market, By Distribution Channels

  • Veterinary Hospitals
  • Veterinary Clinics
  • Retail Pharmacies

Companion Animal Pharmaceuticals Market, By Region

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments:

  • In September 2020, Virbac acquired a range of Tilapia vaccines from Ictyogroup (an animal health company) to distribute and market them worldwide.
  • In June 2020, Merck invested USD 100 million in facility expansion and enhancement efforts in its US manufacturing site in De Soto, Kansas. This site also included an additional expansion of the vaccine production facility, thus enhancing its manufacturing capabilities.
  • In February 2020, Zoetis received FDA approval for Simparica Trio.
  • In February 2019, Zoetis launched Eradia, an antibiotic for dogs, in Europe.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 26)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
           1.2.2 MARKETS COVERED
           FIGURE 1 COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
           TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
    1.4 STAKEHOLDERS
    1.5 LIMITATIONS

2 RESEARCH METHODOLOGY (Page No. - 29)
    2.1 RESEARCH APPROACH
           FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Key industry insights
                    2.1.2.4 Breakdown of primaries
           FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
           FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: ZOETIS
           FIGURE 6 SUPPLY-SIDE ANALYSIS OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET
           FIGURE 7 MARKET ANALYSIS APPROACH
           FIGURE 8 US: COMPANION ANIMAL PHARMACEUTICALS MARKET APPROACH
           FIGURE 9 TOP-DOWN APPROACH
           FIGURE 10 CAGR PROJECTIONS
           FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET (2021–2026): IMPACT ON MARKET GROWTH & CAGR
    2.3 DATA TRIANGULATION APPROACH
           FIGURE 12 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 RISK ASSESSMENT/LIMITATIONS
    2.7 COVID-19 HEALTH ASSESSMENT
    2.8 COVID-19 ECONOMIC ASSESSMENT
    2.9 ASSESSING THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 13 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 14 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY (Page No. - 48)
           FIGURE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2021 VS. 2026 (USD MILLION)
           FIGURE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2021 VS. 2026 (USD MILLION)
           FIGURE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2021 VS. 2026 (USD MILLION)
           FIGURE 18 GEOGRAPHICAL SNAPSHOT OF THE COMPANION ANIMAL  PHARMACEUTICALS MARKET

4 PREMIUM INSIGHTS (Page No. - 52)
    4.1 COMPANION ANIMAL PHARMACEUTICALS MARKET OVERVIEW
           FIGURE 19 RISING PET POPULATION TO DRIVE MARKET GROWTH
    4.2 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET,  BY INDICATION AND COUNTRY (2020)
           FIGURE 20 INFECTIOUS DISEASES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE EUROPEAN MARKET IN 2020
    4.3 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 21 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
    4.4 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (2019–2026)
           FIGURE 22 NORTH AMERICA WILL CONTINUE TO DOMINATE THE COMPANION ANIMAL PHARMACEUTICALS MARKET DURING THE FORECAST PERIOD
    4.5 COMPANION ANIMAL PHARMACEUTICALS MARKET:  DEVELOPED VS. DEVELOPING MARKETS
           FIGURE 23 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           TABLE 2 COMPANION ANIMAL PHARMACEUTICALS MARKET: IMPACT ANALYSIS
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Growing prevalence of zoonotic diseases
           TABLE 3 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2013–2018)
                    5.2.1.2 Rising demand for pet insurance with growing animal health expenditure
           FIGURE 24 US: PET EXPENDITURE, 2010-2019 (USD BILLION)
           FIGURE 25 US: PET HEALTH INSURANCE MARKET, 2014 VS. 2019 (USD MILLION)
                    5.2.1.3 Growing investments by key players
                    5.2.1.4 Initiatives by various government agencies and animal associations
                    5.2.1.5 Growth in companion animal ownership rates
           FIGURE 26 DEVELOPED COUNTRIES: PET POPULATION & PET OWNERSHIP
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 Rising pet care costs
                    5.2.2.2 Limited number of new product developments
                    5.2.2.3 High storage cost of vaccines
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 Lucrative growth opportunities in emerging markets
                    5.2.3.2 Growing prevalence of animal diseases
                    5.2.3.3 Technological advancements in manufacturing vaccines
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Stringent regulatory approval process for drugs
                    5.2.4.2 Inadequate surveillance and reporting systems of vaccines
                    5.2.4.3 Diversity of parasite species

6 INDUSTRY INSIGHTS (Page No. - 67)
    6.1 INTRODUCTION
    6.2 INDUSTRY TRENDS
           6.2.1 GROWING CONSOLIDATION IN THE ANIMAL HEALTHCARE INDUSTRY
           TABLE 4 MAJOR ACQUISITIONS IN THE ANIMAL HEALTH INDUSTRY (2017–2019)
           6.2.2 INNOVATIONS IN ANIMAL HEALTHCARE PRODUCTS
           TABLE 5 INNOVATIVE ANIMAL PHARMACEUTICAL TRENDS
    6.3 PORTER’S FIVE FORCES ANALYSIS
           TABLE 6 PORTER’S FIVE FORCES ANALYSIS
           6.3.1 THREAT OF NEW ENTRANTS
           6.3.2 THREAT OF SUBSTITUTES
           6.3.3 BARGAINING POWER OF SUPPLIERS
           6.3.4 BARGAINING POWER OF BUYERS
           6.3.5 INTENSITY OF COMPETITIVE RIVALRY
    6.4 REGULATORY ANALYSIS
           FIGURE 27 DEVELOPMENT AND APPROVAL PROCESS FOR COMPANION ANIMAL PHARMACEUTICAL PRODUCTS
           TABLE 7 US: RECENT DEVELOPMENTS IN REGULATIONS FOR VETERINARY DRUGS
           FIGURE 28 EUROPE: COMPANION ANIMAL PHARMACEUTICAL PRODUCTS APPROVAL PROCESS
    6.5 VALUE CHAIN ANALYSIS
           FIGURE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS
    6.6 SUPPLY CHAIN ANALYSIS
           FIGURE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS
    6.7 ECOSYSTEM ANALYSIS
           6.7.1 ECOSYSTEM ANALYSIS FOR THE COMPANION ANIMAL PHARMACEUTICALS MARKET
           FIGURE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS
    6.8 IMPACT OF COVID-19 ON THE COMPANION ANIMAL PHARMACEUTICALS MARKET
    6.9 PATENT ANALYSIS
           6.9.1 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICALS
           FIGURE 32 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICAL PATENTS (2015–2020)
           6.9.2 TOP INVENTORS FOR COMPANION ANIMAL PHARMACEUTICALS
           FIGURE 33 TOP INVENTORS FOR COMPANION ANIMAL PHARMACEUTICALS PATENTS (2015–2020)
           6.9.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR COMPANION ANIMAL PHARMACEUTICALS
           FIGURE 34 TOP APPLICANT COUNTRIES FOR COMPANION ANIMAL PHARMACEUTICAL PATENTS (2015–2020)

7 COMPANION ANIMAL PHARMACEUTICALS MARKET,  BY INDICATION (Page No. - 84)
    7.1 INTRODUCTION
           TABLE 8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
    7.2 INFECTIOUS DISEASES
           TABLE 9 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 10 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.1 PARASITICIDES
                    7.2.1.1 Growing regulatory guidelines to prevent the spread of parasite-caused diseases is fueling the market growth
           TABLE 11 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.2 VACCINES
                    7.2.2.1 Rising awareness among pet owners for vaccinating dogs and cats to drive market growth
           TABLE 12 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.3 ANTIBIOTICS AND ANTIMICROBIALS
                    7.2.3.1 Antibiotics and antimicrobials help combat clinical and subclinical diseases in animals
           TABLE 13 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS AND ANTIMICROBIALS, BY COUNTRY, 2019–2026 (USD MILLION)
           7.2.4 OTHER COMPANION ANIMAL PHARMACEUTICALS
           TABLE 14 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMAL PHARMACEUTICALS, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 DERMATOLOGIC DISEASES
           7.3.1 GROWING CASES OF DERMATOLOGIC DISEASES HAVE INCREASED THE DEMAND FOR VETERINARY PHARMACEUTICALS
           TABLE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DERMATOLOGIC DISEASES,  BY COUNTRY, 2019–2026 (USD MILLION)
    7.4 PAIN
           7.4.1 RISING PREVALENCE OF MUSCULOSKELETAL DISORDERS TO DRIVE SUPPORT MARKET GROWTH
           TABLE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PAIN, BY COUNTRY,  2019–2026 (USD MILLION)
    7.5 ORTHOPEDIC DISEASES
           7.5.1 GROWING PREVALENCE OF OSTEOARTHRITIS AND THE INCREASING POPULATION OF OBESE PETS HAS INCREASED THE DEMAND FOR ORTHOPEDIC DRUGS
           TABLE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORTHOPEDIC DISEASES,  BY COUNTRY, 2019–2026 (USD MILLION)
    7.6 BEHAVIORAL DISORDERS
           7.6.1 GROWING AWARENESS AMONG PET OWNERS REGARDING BEHAVIORAL DISORDERS IS EXPECTED TO FUEL THE DEMAND FOR THESE DRUGS
           TABLE 18 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DISORDERS,  BY COUNTRY, 2019–2026 (USD MILLION)
    7.7 OTHER INDICATIONS
           TABLE 19 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER INDICATIONS,  BY COUNTRY, 2019–2026 (USD MILLION)

8 COMPANION ANIMAL PHARMACEUTICALS MARKET,  BY ANIMAL TYPE (Page No. - 102)
    8.1 INTRODUCTION
           TABLE 20 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
    8.2 DOGS
           8.2.1 DOGS SEGMENT IS EXPECTED TO DOMINATE THE GLOBAL MARKET DURING THE FORECAST PERIOD
           FIGURE 35 POPULATION OF PET DOGS IN INDIA (MILLION)
           FIGURE 36 POPULATION OF PET DOGS GLOBALLY (MILLION)
           TABLE 21 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY,  2019–2026 (USD MILLION)
    8.3 CATS
           8.3.1 GROWING RESEARCH ON FELINE HEALTH AND WELLBEING TO SUPPORT THE MARKET GROWTH
           TABLE 22 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY,  2019–2026 (USD MILLION)
    8.4 HORSES
           8.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES IN THE EQUINE POPULATION TO DRIVE MARKET GROWTH
           TABLE 23 HORSE POPULATION, BY REGION, 2016–2019 (MILLION)
           TABLE 24 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY,  2019–2026 (USD MILLION)
    8.5 OTHER COMPANION ANIMALS
           TABLE 25 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2019–2026 (USD MILLION)

9 COMPANION ANIMAL PHARMACEUTICALS MARKET,  BY DISTRIBUTION CHANNEL (Page No. - 111)
    9.1 INTRODUCTION
           TABLE 26 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL,  2019–2026 (USD MILLION)
    9.2 VETERINARY HOSPITALS
           9.2.1 VETERINARY HOSPITALS ARE THE LARGEST AND FASTEST-GROWING SEGMENT OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET
           TABLE 27 VETERINARY VISIT EXPENSES FOR CATS AND DOGS IN THE US
           TABLE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS,  BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 VETERINARY CLINICS
           9.3.1 INCREASING NUMBER OF PRIVATE CLINICAL PRACTICES TO SUPPORT MARKET GROWTH
           TABLE 29 NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY, 2015 VS. 2019
           TABLE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY CLINICS,  BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 RETAIL PHARMACIES
           9.4.1 EASY ACCESSIBILITY OF PHARMACEUTICALS THROUGH PRESCRIPTION AND OTC TO SUPPORT THE MARKET GROWTH
           TABLE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES,  BY COUNTRY, 2019–2026 (USD MILLION)

10 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (Page No. - 118)
     10.1 INTRODUCTION
           TABLE 32 COMPANION ANIMAL POPULATION, BY COUNTRY, 2020 (THOUSAND)
           FIGURE 37 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT
           TABLE 33 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION,  2019–2026 (USD MILLION)
     10.2 NORTH AMERICA
           FIGURE 38 EXPECTED GROWTH IN THE NUMBER OF VETERINARIANS IN NORTH AMERICA
           FIGURE 39 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT
           TABLE 34 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 35 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
           TABLE 36 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 37 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
           TABLE 38 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.2.1 US
                        10.2.1.1 The US dominates the North American companion animal pharmaceuticals market
           FIGURE 40 US: INCREASE IN PET EXPENDITURE, 2010–2019 (USD BILLION)
           TABLE 39 US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2016 VS. 2018
           TABLE 40 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 41 US: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES,  BY TYPE, 2019–2026 (USD MILLION)
           TABLE 42 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 43 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Increasing pet adoption rate and rising animal health awareness to support market growth in Canada
           TABLE 44 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 45 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 46 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 47 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
     10.3 EUROPE
           TABLE 48 EUROPE: NUMBER OF VETERINARIANS, 2012–2018
           TABLE 49 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY,  2019–2026 (USD MILLION)
           TABLE 50 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 51 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 52 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 53 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Germany held the largest share of the European market in 2020
           TABLE 54 GERMANY: COMPANION ANIMAL POPULATION, 2012–2018 (MILLION)
           TABLE 55 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 56 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 57 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 58 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Growing pet ownership rates to drive market growth
           TABLE 59 UK: COMPANION ANIMAL POPULATION, 2010–2018 (MILLION)
           TABLE 60 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 61 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES,  BY TYPE, 2019–2026 (USD MILLION)
           TABLE 62 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 63 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Presence of major players in the country is expected to propel the companion animal pharmaceuticals market
           TABLE 64 FRANCE: COMPANION ANIMAL POPULATION, 2010–2018 (MILLION)
           TABLE 65 FRANCE: NUMBER OF VETERINARIANS, 2014 VS. 2016 VS. 2018
           TABLE 66 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 67 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 68 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 69 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.3.4 SPAIN
                        10.3.4.1 Increasing animal health expenditure is propelling market growth in Spain
           TABLE 70 SPAIN: COMPANION ANIMAL POPULATION, 2014–2018 (MILLION)
           TABLE 71 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 72 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 73 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 74 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Growing animal healthcare expenditure to support market growth
           TABLE 75 ITALY: COMPANION ANIMAL POPULATION, 2016–2018 (MILLION)
           TABLE 76 ITALY: NUMBER OF VETERINARIANS, 2016 VS. 2019
           TABLE 77 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 78 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES,  BY TYPE, 2019–2026 (USD MILLION)
           TABLE 79 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 80 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.3.6 REST OF EUROPE
           TABLE 81 ROE: COMPANION ANIMAL OWNERSHIP, 2018 (MILLION)
           TABLE 82 COMPANION ANIMAL POPULATION IN THE REST OF EUROPE, 2019 (MILLION)
           TABLE 83 ROE: NUMBER OF VETERINARIANS AND PARAVETERINARIANS, 2016 VS. 2019
           TABLE 84 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 85 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES,  BY TYPE, 2019–2026 (USD MILLION)
           TABLE 86 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 87 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
     10.4 ASIA PACIFIC
           FIGURE 41 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT
           TABLE 88 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY,  2019–2026 (USD MILLION)
           TABLE 89 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
           TABLE 90 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 91 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
           TABLE 92 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 China dominates the companion animal pharmaceuticals market
           FIGURE 42 CHINA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
           TABLE 93 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 94 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 95 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 96 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Rising demand for imported breeds is driving pet adoption rates in the country
           TABLE 97 JAPAN: NUMBER OF VETERINARIANS, 2016 VS. 2019
           TABLE 98 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 99 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 100 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 101 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 India is an untapped market with large growth potential in companion animal pharmaceuticals
           FIGURE 43 INDIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
           TABLE 102 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 103 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES,  BY TYPE, 2019–2026 (USD MILLION)
           TABLE 104 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 105 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.4.4 SOUTH KOREA
                        10.4.4.1 Rising pet population and growing awareness about animal health to support market growth
           TABLE 106 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
           TABLE 107 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 108 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
           TABLE 109 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
           FIGURE 44 AUSTRALIA: PROJECTED COMPANION ANIMAL POPULATION,  2018–2025 (MILLION)
           TABLE 110 ROAPAC: NUMBER OF VETERINARIANS, 2012−2019
           TABLE 111 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION,  2019–2026 (USD MILLION)
           TABLE 112 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 113 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE,  2019–2026 (USD MILLION)
           TABLE 114 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
     10.5 LATIN AMERICA
             10.5.1 RISING POOL OF SKILLED VETERINARIANS AND GROWING PET HEALTH EXPENDITURE TO DRIVE THE MARKET GROWTH
           TABLE 115 NUMBER OF VETERINARIANS AND VETERINARY PARA-PROFESSIONALS IN LATIN AMERICAN COUNTRIES, 2016 VS. 2019
           TABLE 116 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION)
           TABLE 117 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 118 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
           TABLE 119 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA
             10.6.1 GROWING POPULATION OF COMPANION ANIMALS TO PROPEL MARKET GROWTH
           TABLE 120 AFRICA: NUMBER OF VETERINARIANS, 2012 VS. 2017 VS. 2019
           TABLE 121 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET,  BY INDICATION, 2019–2026 (USD MILLION)
           TABLE 122 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION)
           TABLE 123 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION)
           TABLE 124 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET,  BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 168)
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES ADOPTED BY MARKET PLAYERS FROM JANUARY 2017 TO FEBRUARY 2021
     11.3 GEOGRAPHICAL FOOTPRINT OF THE MAJOR PLAYERS IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET
           FIGURE 45 GEOGRAPHIC REVENUE MIX: COMPANION ANIMAL PHARMACEUTICALS MARKET (2020)
     11.4 COMPANY PRODUCT FOOTPRINT
           FIGURE 46 PRODUCT PORTFOLIO ANALYSIS: COMPANION ANIMAL PHARMACEUTICALS MARKET
     11.5 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS
           FIGURE 47 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET (2015–2019)
     11.6 MARKET SHARE ANALYSIS
           FIGURE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2020
     11.7 MARKET EVALUATION FRAMEWORK
           FIGURE 49 MARKET EVALUATION FRAMEWORK: ACQUISITIONS—THE MOST WIDELY ADOPTED STRATEGY
     11.8 COMPETITIVE LEADERSHIP MAPPING
             11.8.1 STARS
             11.8.2 EMERGING LEADERS
             11.8.3 PERVASIVE PLAYERS
             11.8.4 PARTICIPANTS
           FIGURE 50 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
     11.9 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS
             11.9.1 PROGRESSIVE COMPANIES
             11.9.2 DYNAMIC COMPANIES
             11.9.3 STARTING BLOCKS
             11.9.4 RESPONSIVE COMPANIES
           FIGURE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020)
     11.10 COMPETITIVE SITUATION AND TRENDS
             11.10.1 PRODUCT LAUNCHES & APPROVALS
           TABLE 125 PRODUCT LAUNCHES & APPROVALS
             11.10.2 EXPANSIONS
           TABLE 126 EXPANSIONS
             11.10.3 ACQUISITIONS
           TABLE 127 ACQUISITIONS
             11.10.4 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
           TABLE 128 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS

12 COMPANY PROFILES (Page No. - 185)
     12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, MnM View)* 
             12.1.1 ZOETIS INC.
           TABLE 129 ZOETIS INC.: BUSINESS OVERVIEW
           FIGURE 52 ZOETIS: COMPANY SNAPSHOT (2020)
             12.1.2 MERCK & CO., INC.
           TABLE 130 MERCK & CO., INC.: BUSINESS OVERVIEW
           FIGURE 53 MERCK & CO., INC.: COMPANY SNAPSHOT (2020)
             12.1.3 BOEHRINGER INGELHEIM GMBH
           TABLE 131 BOEHRINGER INGELHEIM GMBH: BUSINESS OVERVIEW
           FIGURE 54 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2019)
             12.1.4 ELANCO ANIMAL HEALTH INCORPORATED
           TABLE 132 ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW
           FIGURE 55 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2019)
             12.1.5 CEVA SANTΙ ANIMALE
           TABLE 133 CEVA SANTΙ ANIMALE: BUSINESS OVERVIEW
             12.1.6 VIRBAC
           TABLE 134 VIRBAC: BUSINESS OVERVIEW
           FIGURE 56 VIRBAC: COMPANY SNAPSHOT (2019)
             12.1.7 VETOQUINOL S.A.
           TABLE 135 VETOQUINOL S.A.: BUSINESS OVERVIEW
           FIGURE 57 VETOQUINOL S.A.: COMPANY SNAPSHOT (2019)
             12.1.8 DECHRA PHARMACEUTICALS PLC
           TABLE 136 DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW
           FIGURE 58 DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2019)
             12.1.9 CHANELLE PHARMA
           TABLE 137 CHANELLE PHARMA: BUSINESS OVERVIEW
             12.1.10 KYORITSU SEIYAKU
           TABLE 138 KYORITSU SEIYAKU: BUSINESS OVERVIEW
             12.1.11 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED
           TABLE 139 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED: BUSINESS OVERVIEW
           FIGURE 59 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED: COMPANY SNAPSHOT (2019)
             12.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.
           TABLE 140 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW
             12.1.13 HIPRA
           TABLE 141 HIPRA: BUSINESS OVERVIEW
             12.1.14 NORBROOK HOLDINGS LIMITED
           TABLE 142 NORBROOK HOLDINGS LIMITED: BUSINESS OVERVIEW
             12.1.15 INOVET
           TABLE 143 INOVET: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS
             12.2.1 ENDOVAC ANIMAL HEALTH
             12.2.2 ECO ANIMAL HEALTH GROUP PLC
             12.2.3 INDIAN IMMUNOLOGICALS LTD.
             12.2.4 ASHISH LIFE SCIENCE PVT. LTD.
             12.2.5 LUTIM PHARMA PVT. LTD.
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies. 

13 APPENDIX (Page No. - 231)
     13.1 INSIGHTS FROM INDUSTRY EXPERTS
     13.2 DISCUSSION GUIDE
     13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.4 AVAILABLE CUSTOMIZATIONS
     13.5 RELATED REPORTS
     13.6 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

Secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Business, Factiva, and D&B Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the companion animal pharmaceuticals market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the companion animal pharmaceuticals market. The primary sources from the demand side include industry experts such as experts from veterinary hospitals, clinics, research institutes, retail pharmacies, and contract manufacturing organizations.

Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

A breakdown of the primary respondents for companion animal pharmaceuticals market is provided below:

Companion Animal Pharmaceuticals Market   Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by indication, by animal type, by distribution channels, and by region).

Data Triangulation

After arriving at the market size, the total companion animal pharmaceuticals  market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, segment, and forecast the companion animal pharmaceuticals market by indication, animal type, distribution channel, and region
  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall companion animal pharmaceuticals market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the companion animal pharmaceuticals market in five main regions along with their respective key countries, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the companion animal pharmaceuticals market and comprehensively analyze their core competencies2 and market shares
  • To track and analyze competitive developments, such as acquisitions, product launches, expansions, and partnerships of the leading players in the companion animal pharmaceuticals market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific companion animal pharmaceuticals market into Australia, New Zealand, and others
  • Further breakdown of the Latin American companion animal pharmaceuticals market into Brazil, Mexico, and the Rest of Latin America

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)
COVID-19

Get in-depth analysis of the COVID-19 impact on the Companion Animal Pharmaceuticals Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Companion Animal Pharmaceuticals Market

Request For Special Pricing
Report Code
MD 7870
Published ON
Apr, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Companion Animal Pharmaceuticals Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home